GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (NAS:VIVO) » Definitions » Cash Flow from Investing

Meridian Bioscience (Meridian Bioscience) Cash Flow from Investing : $-11.1 Mil (TTM As of Sep. 2022)


View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2022, Meridian Bioscience spent $3.5 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $0.0 Mil on purchasing investments. It gained $0.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it received $1.3 Mil from other investing activities. In all, Meridian Bioscience spent $2.2 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2022.


Meridian Bioscience Cash Flow from Investing Historical Data

The historical data trend for Meridian Bioscience's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience Cash Flow from Investing Chart

Meridian Bioscience Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.20 -48.45 -54.60 -40.40 -11.12

Meridian Bioscience Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.99 -1.71 -1.47 -5.71 -2.23

Meridian Bioscience Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Meridian Bioscience's Cash Flow from Investing for the fiscal year that ended in Sep. 2022 is calculated as:

Meridian Bioscience's Cash Flow from Investing for the quarter that ended in Sep. 2022 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Meridian Bioscience  (NAS:VIVO) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Meridian Bioscience's purchase of property, plant, equipment for the three months ended in Sep. 2022 was $-3.5 Mil. It means Meridian Bioscience spent $3.5 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Meridian Bioscience's sale of property, plant, equipment for the three months ended in Sep. 2022 was $0.0 Mil. It means Meridian Bioscience gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Meridian Bioscience's purchase of business for the three months ended in Sep. 2022 was $0.0 Mil. It means Meridian Bioscience spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Meridian Bioscience's sale of business for the three months ended in Sep. 2022 was $0.0 Mil. It means Meridian Bioscience gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Meridian Bioscience's purchase of investment for the three months ended in Sep. 2022 was $0.0 Mil. It means Meridian Bioscience spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Meridian Bioscience's sale of investment for the three months ended in Sep. 2022 was $0.0 Mil. It means Meridian Bioscience gained $0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Meridian Bioscience's net Intangibles purchase and sale for the three months ended in Sep. 2022 was $0.0 Mil. It means Meridian Bioscience paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Meridian Bioscience's cash from discontinued investing activities for the three months ended in Sep. 2022 was 0.0 Mil. It means Meridian Bioscience paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Meridian Bioscience's cash from other investing activities for the three months ended in Sep. 2022 was $1.3 Mil. It means Meridian Bioscience received $1.3 Mil from other investing activities.


Meridian Bioscience Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Meridian Bioscience (Meridian Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
3471 River Hills Drive, Cincinnati, OH, USA, 45244
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.
Executives
Julie Diana Smith officer: Sr VP, Controller, PAO 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John P. Kenny director, officer: Chief Executive Officer 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Andrew S. Kitzmiller officer: EVP & CFO ONE BATESVILLE BLVD., BATESVILLE IN 47006
Bryan T Baldasare officer: Interim CFO & Chief Acctg Off 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Rice John Mccune Jr. director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Bihl Anthony P Iii director 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Tony Serafini-lamanna officer: Executive VP-Diagnostics 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Felicia Williams director C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001
John Mcilwraith director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
David Phillips director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
James M. Anderson director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Dwight E Ellingwood director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lawrence Baldini officer: Exec VP, Operations & IS 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric S. Rasmussen officer: EVP, Bus. Development/Strategy 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lourdes Weltzien officer: EVP, Life Science 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244

Meridian Bioscience (Meridian Bioscience) Headlines